MedPage Today December 12, 2024
Shannon Firth

— Patent thickets another key target

Policy experts punched holes in drug companies’ claims that the Medicare Drug Price Negotiation Program will stunt innovation and weighed in on other drug price-curbing strategies during a webinar hosted by the National Institute for Health Care Management (NIHCM) Foundation on Wednesday.

The Backlash to Medicare Drug Price Negotiation

A number of pharmaceutical companies and other stakeholders have fought the drug price negotiation program in courts, with some arguing that the program will stifle innovation and reduce access to drugs for vulnerable patients.

However, Gregg Girvan, MPP, a fellow for the Foundation for Research on Equal Opportunity (FREOPP), said the policy won’t be nearly as damaging to innovation as pharmaceutical companies have warned.

Girvan...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
Related Articles:
State Policy Levers Can Increase Enrollment In Medicare Savings Programs
ACP expresses support for proposed Medicare $2 Drug List Model
An Introduction to MIPS Basics
How Healthcare Leaders Reacted to the 15 Additional Drugs Selected for Medicare Negotiation Program
Lawmakers, experts weigh in on Medicare Drug Price Negotiation Program

Share This Article